Brii Biosciences Limited
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII…
Biotechnology
CN, Beijing [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 0.00 | 22.11 | 22.11 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -0.64 | 3.54 | 3.56 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | 0.00 | 4.28 | 4.28 | |
| Cash | 0.00 | 3.65 | 3.65 | |
| Capex | 0.00 | 0.00 | 0.00 | |
| Free Cash Flow | 0.00 | -0.16 | -0.16 | |
| Revenue | 0.00 | 0.01 | 0.01 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 0.00 | 1.00 | 1.00 | |
| Operating Margin | 0.00 | -17.14 | -17.14 | |
| ROA | 0.00 | < 0.005 | < 0.005 | |
| ROE | 0.00 | < 0.005 | < 0.005 | |
| ROIC | 0.10 | -0.05 | -0.05 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of 2137.HK is permitted for members.
5
Growth
The "Growth Entry" for the Focus of 2137.HK is permitted for members.
6
Leverage & Liquidity